Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse

Leuk Lymphoma. 2022 Nov;63(11):2743-2746. doi: 10.1080/10428194.2022.2090553. Epub 2022 Jun 22.

Affiliation

¹ Hematology and BMT Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

PMID: 35730459
DOI: 10.1080/10428194.2022.2090553

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Leukemia, Myeloid, Acute* / drug therapy
Off-Label Use
Recurrence

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic